That is, compared to insulin, 57 and 30 patients would need to be treated with a GLP-1RA for a mean of 2.3 years to prevent one case of all-cause mortality and hospitalized hypoglycemia, respectively, which would cost US$54,851 and US$29,115 per case of all-cause mortality and hospitalized hypoglycemia prevented, respectively, from the payer perspective, and would save US$19,391 and US$10,293, respectively, from the healthcare sector perspective
These include chemicals, drugs and biological substances such as bacterial or viral antigens
Image Credit: Edugrafo / Shutterstock.com Introduction Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have transformed the treatment of metabolic conditions such as obesity and diabetes
Discover your ideal supplement here
can we discuss what this means for my dose?" This collaborative approach is the hallmark of the Blue Horizon Method